Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 2/2016

01-04-2016 | SHORT REPORT

Targeting BRAF mutants in clear-cell sarcomas of soft tissue: beyond sarcoma or melanoma classification

Authors: Arnaud Uguen, Pascale Marcorelles, Marc De Braekeleer

Published in: Investigational New Drugs | Issue 2/2016

Login to get access

Excerpt

To the Editor, …
Literature
1.
Protsenko SA, Semionova AI, Komarov YI, Aleksakhina SN, Ivantsov AO, Iyevleva AG, Imyanitov EN (2015) BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. Investig New Drugs 33:1136–1143CrossRef
2.
Hocar O, Le CA, Berissi S, Terrier P, Bonvalot S, Vanel D, Auperin A, Le Pechoux C, Bui B, Coindre JM, Robert C (2012) Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases. Dermatol Res Pract 2012:984096PubMedPubMedCentral
3.
Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, Lipson D, Otto G, Brennan K, Murali R, Garrido M, Miller VA, Ross JS, Berger MF, Sparatta A, Palmedo G, Cerroni L, Busam KJ, Kutzner H, Cronin MT, Stephens PJ, Bastian BC (2014) Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 5:3116PubMedPubMedCentral
Metadata
Title
Targeting BRAF mutants in clear-cell sarcomas of soft tissue: beyond sarcoma or melanoma classification
Authors
Arnaud Uguen
Pascale Marcorelles
Marc De Braekeleer
Publication date
01-04-2016
Publisher
Springer US
Published in
Investigational New Drugs / Issue 2/2016
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-015-0319-2

Other articles of this Issue 2/2016

Investigational New Drugs 2/2016 Go to the issue

PRECLINICAL STUDIES

The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15

SHORT REPORT

Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib

PHASE I STUDIES

A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors

PRECLINICAL STUDIES

Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats

PHASE I STUDIES

Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects

PHASE I STUDIES

Pharmacokinetics, metabolism, and excretion of 14C-labeled belinostat in patients with recurrent or progressive malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits